Campbell University
CU FIND (Campbell University, Catherine W. Wood School of Nursing)Not a member yet
9287 research outputs found
Sort by
Policy on Policies and Procedures
No full textThe purpose of this policy is to ensure that the Campbell University community has ready access to well-developed and understandable university policies
Record Retention Policy
No full textCampbell University requires that different types of hard copy and electronic documents, records, and other sources of data (collectively “records”) be retained for specified periods of time consistent with university business needs and legal requirements, including, but not limited to, privacy laws, United States Department of Education regulations, and financial aid program requirements. This policy sets forth the standards and procedures for use by Campbell in connection with the retention and disposal of records
Investigating the mechanism of prolotherapy: the fibroblast response to dextrose in vitro
No full textSynthetic cannabinoid receptor agonists compared to Δ9-tetrahydrocannabinol: Neurological effects and beyond
No full textThe amino terminal domain regulates the electrogenecity whereas the carboxyl terminal domain mediates the targeting of NBC1 to the basolateral membrane
No full text
Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research
No full textBACKGROUND: Metformin is among the most frequently prescribed antidiabetic drugs worldwide and remains the first-line therapy for type 2 diabetes due to its well-established glucose-lowering efficacy and favorable safety profile. SUMMARY: Studies over the past decades show that metformin also exerts many other beneficial effects independent of its glucose-lowering effect both in experimental models and human subjects. Among them, the most notable is its cardiovascular protective effect. In this review, we discuss the latest cutting-edge research findings on metformin\u27s cardiovascular protection from both preclinical studies and randomized clinical trials. We focus on describing novel basic research discoveries reported in influential journals and discussing their implications in the context of latest clinical trial findings related to common cardiovascular and metabolic disorders, including atherosclerosis and dyslipidemia, myocardial injury, and heart failure. KEY MESSAGES: While substantial preclinical and clinical evidence suggests metformin as a potential cardiovascular protectant, large-scale randomized controlled trials are warranted to establish its clinical efficacy in treating patients with atherosclerotic cardiovascular disease and heart failure
